These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

410 related articles for article (PubMed ID: 16919075)

  • 1. Recombinant factor VIIa in paediatric bleeding disorders--a 2006 review.
    Mathew P; Young G
    Haemophilia; 2006 Sep; 12(5):457-72. PubMed ID: 16919075
    [TBL] [Abstract][Full Text] [Related]  

  • 2. To general haemostasis--the evidence-based route.
    Erhardtsen E
    Pathophysiol Haemost Thromb; 2002; 32 Suppl 1():47-52. PubMed ID: 12214148
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dose effect and efficacy of rFVIIa in the treatment of haemophilia patients with inhibitors: analysis from the Hemophilia and Thrombosis Research Society Registry.
    Parameswaran R; Shapiro AD; Gill JC; Kessler CM;
    Haemophilia; 2005 Mar; 11(2):100-6. PubMed ID: 15810910
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The use of rFVIIa in non-haemophilia bleeding conditions in paediatrics. A systematic review.
    Mathew P
    Thromb Haemost; 2004 Oct; 92(4):738-46. PubMed ID: 15467904
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Experience with recombinant-activated factor VII in 30 patients with congenital factor VII deficiency.
    Brenner B; Wiis J
    Hematology; 2007 Feb; 12(1):55-62. PubMed ID: 17364994
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recombinant factor VIIa in the management of surgery and acute bleeding episodes in children with haemophilia and high-responding inhibitors.
    Smith OP
    Pathophysiol Haemost Thromb; 2002; 32 Suppl 1():22-5. PubMed ID: 12214142
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recombinant factor VIIa: a review on its clinical use.
    Franchini M
    Int J Hematol; 2006 Feb; 83(2):126-38. PubMed ID: 16513530
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potential role of recombinant factor VIIa as a hemostatic agent.
    Hedner U; Erhardtsen E
    Clin Adv Hematol Oncol; 2003 Feb; 1(2):112-9. PubMed ID: 16224390
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of recombinant factor VIIa administered by continuous infusion to haemophilia patients with inhibitors.
    Mauser-Bunschoten EP; Koopman MM; Goede-Bolder AD; Leebeek FW; van der Meer J; van Marwijk Kooij GM; van der Linden PW;
    Haemophilia; 2002 Sep; 8(5):649-56. PubMed ID: 12199674
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recombinant-activated coagulation factor VIIa (NovoSeven): current development.
    Weiskopf RB
    Vox Sang; 2007 May; 92(4):281-8. PubMed ID: 17456151
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comprehensive review of rFVIIa use in a tertiary care pediatric center.
    Heller M; Lau W; Pazmino-Canizares J; Brandão LR; Carcao M
    Pediatr Blood Cancer; 2008 May; 50(5):1013-7. PubMed ID: 17960639
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overall experience with NovoSeven.
    Négrier C; Lienhart A
    Blood Coagul Fibrinolysis; 2000 Apr; 11 Suppl 1():S19-24. PubMed ID: 10850559
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dose optimization of recombinant factor VIIa in the treatment of acute bleeding in haemophilia-associated inhibitors.
    Seremetis S
    Blood Coagul Fibrinolysis; 2003 Jun; 14 Suppl 1():S29-30. PubMed ID: 14567532
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prophylactic treatment of haemophilia patients with inhibitors: clinical experience with recombinant factor VIIa in European Haemophilia Centres.
    Morfini M; Auerswald G; Kobelt RA; Rivolta GF; Rodriguez-Martorell J; Scaraggi FA; Altisent C; Blatny J; Borel-Derlon A; Rossi V
    Haemophilia; 2007 Sep; 13(5):502-7. PubMed ID: 17880436
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Utilization of recombinant activated factor VII in southern Ontario in 85 patients with and without haemophilia.
    Webert KE; Arnold DM; Carruthers J; Molnar L; Almonte T; Decker K; Seroski W; Reed J; Chan AK; Pai M; Walker IR
    Haemophilia; 2007 Sep; 13(5):518-26. PubMed ID: 17880438
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exposure and safety of higher doses of recombinant factor VIIa ≥250 μg kg(-1) in individuals with congenital haemophilia complicated by alloantibody inhibitors: the Haemophilia and Thrombosis Research Society Registry experience (2004-2008).
    Neufeld EJ; Kessler CM; Gill JC; Wilke CT; Cooper DL;
    Haemophilia; 2011 Jul; 17(4):650-6. PubMed ID: 21299750
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The evidence behind inhibitor treatment with recombinant factor VIIa.
    Ludlam CA
    Pathophysiol Haemost Thromb; 2002; 32 Suppl 1():13-8. PubMed ID: 12214140
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recombinant factor VIIa. An update on its clinical use.
    Franchini M; Zaffanello M; Veneri D
    Thromb Haemost; 2005 Jun; 93(6):1027-35. PubMed ID: 15968384
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The evidence for the use of recombinant factor VIIa in massive bleeding: development of a transfusion policy framework.
    Moltzan CJ; Anderson DA; Callum J; Fremes S; Hume H; Mazer CD; Poon MC; Rivard G; Rizoli S; Robinson S
    Transfus Med; 2008 Apr; 18(2):112-20. PubMed ID: 18399845
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Management of oral bleedings with recombinant factor VIIa in children with haemophilia A and inhibitor.
    Laguna P; Klukowska A
    Haemophilia; 2005 Jan; 11(1):2-4. PubMed ID: 15660981
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.